Japanese Prostate Cancer Imaging Trial Meets Study Objectives
February 07, 2022 18:08 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and KYOTO, Japan, Feb. 08, 2022 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) in collaboration with Kanazawa University today announces that...
Japanese Prostate Cancer Imaging Study Completes Enrolment
September 08, 2021 18:57 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and KYOTO, Japan, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the last patient has been imaged in a...
Mr. Ryoichi Tanaka Joins Telix Japan as Chief Operating Officer
August 05, 2021 18:14 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and KYOTO Japan, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, ‘Telix’, the ‘Company’) is pleased to announce that Mr. Ryoichi Tanaka has joined the...
First Patient Dosed in Japanese Prostate Cancer Imaging Study
May 24, 2021 21:04 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and KYOTO, Japan, May 25, 2021 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the first patient has been dosed in a...